Company / Operating Income
Sarepta Therapeutics Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$699.8M
FY2025
5-year range
-$699.8M / $218.1M
FY2021-FY2025
Trend
-420.9%
vs FY2024
Sector context
#194 of 204
Health Care
What the data says
Operating Income changed -421% YoY in FY2025, a notable deviation from the 9-year average annual change of -40%.
Based on SEC 10-K filings.
-$700M in FY2025.
Declined from -$268M to -$700M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 204This company -$699.8M Sector average $107.7M
▼
-749.6% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 420.9% year-over-year.
- Ranks #194 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$699.8M | -420.9% |
| FY2024 | $218.1M | +181.4% |
| FY2023 | -$267.8M | +52.5% |
| FY2022 | -$564.2M | -22.7% |
| FY2021 | -$459.7M | -33.8% |
| FY2020 | -$343.6M | -100.2% |
| FY2019 | -$171.6M | +50.1% |
| FY2018 | -$343.6M | -100.2% |
| FY2017 | -$171.6M | +35.7% |
| FY2016 | -$266.7M | -21.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026